Study on the influence of Topiroxostat on renal functio
Not Applicable
- Conditions
- hyperuricemia
- Registration Number
- JPRN-UMIN000034118
- Lead Sponsor
- Sato Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 59
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with history of hemodialysis or peritoneal dialysis within 3 months before or after the administration of topiroxostat, or before eGFR of less than 30, or before the start date of topioxastat administration 2. Patients taking other uric acid-lowering drugs (Febuxostat, Allopurinol, Benzbromarone, Probenecid, Bucolome) (including switching from other uric acid lowering drugs)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eGFR change amount from pre-administration value 6 months after administration
- Secondary Outcome Measures
Name Time Method Change rate of eGFR Amount of change in urine albumin Serum uric acid Adverse event